Were the EMPA-REG Renal results chance, or is this a class effect? Let's take a deep dive into CANVAS, published in the NEJM recently, which examined the cardiovascular safety of canaglifozin in type 2 diabetes.
This week we will be discussing the KALM-1 trial which was presented at the Late Breaking and High Impact Trial Session at the recently completed #KidneyWk. It was simultaneously published in the NEJM. Kalm-1 investigated whether difelikefalin, a opioid kappa agonist, decreased uremic pruritus.
#KidneyWkBingo is back!
The NephJC poster tours return for another run at #KidneyWk
Details of the #NephJC tweetup. 2019 edition
NephJC needs your help. Time to open your wallet and help keep the lights on at NephJC HQ. Also score some pretty fly NephJC fleece, hats and tote bags. (Yeah, we know that there has never been a “fly” tote bag. Work with us.